Investment Rating - The report does not explicitly state an investment rating for the pharmaceutical industry [2]. Core Insights - During the period from March 9 to March 15, 2026, a total of 98 innovative drugs/improved new drugs were submitted for clinical trials or market approval, with 82 domestic and 16 imported applications [8]. - A total of 86 innovative drugs/improved new drugs received "implied permission" for clinical trials, including 48 chemical drugs and 37 biological drugs [8]. - Notable drugs include SG-12 injection for chronic hepatitis B and SKB-575 injection for atopic dermatitis, both of which received clinical trial approval [9][10]. Summary by Sections 1. Domestic Innovative Drugs/Improved New Drugs - 1.1 Overview: 98 applications for clinical trials or market approval were recorded, with 82 domestic and 16 imported [8]. - 1.2 Clinical Trial Approvals: 86 drugs received implied permission for clinical trials, including significant drugs like SG-12 and SKB-575 [8][9]. - 1.3 Market Approvals: No new drugs were approved for market this week [29]. 2. Domestic Generic Drugs/Biosimilars - 2.1 Overview: 41 applications for generic drugs were submitted, with 36 for new registration and 4 for clinical trials [30]. - 2.2 Consistency Evaluation: 6 products passed consistency evaluation, with a total of 55 products deemed equivalent [31]. 3. Policy and Regulation - 3.1 Policy Overview: The report summarizes key policies affecting the pharmaceutical industry, including the implementation of the Drug Administration Law [3]. - 3.2 Detailed Policy Explanation: Specific regulations and their implications for the industry are discussed [3]. 4. Global Innovative Drug Development - 4.1 Global R&D Overview: The report highlights the progress of the top 10 innovative drugs globally, including significant approvals and clinical trial results [4]. - 4.2 Clinical Trial Outcomes: The report details both successful and failed clinical trials for various drugs, indicating the competitive landscape [4].

Investment Rating - The report does not explicitly state an investment rating for the industry Core Insights - The global biopharmaceutical industry is experiencing a surge in capital market activities, with numerous collaborations and financing deals taking place, indicating a robust investment environment [4][16] - Significant clinical advancements are reported in various therapeutic areas, including metabolic diseases, oncology, and immunology, showcasing the industry's innovation potential [5][8] - The trend of accelerating capitalizations and upgrading research and development models is evident, with companies increasingly focusing on AI-driven drug development and advanced therapeutic modalities [5][16] Summary by Sections Global Biopharmaceutical Industry Dynamics - The report highlights a series of strategic collaborations and financing activities, including Yuan Yi Bio's acquisition of CNS drug RAP-219 rights for up to $328 million and GSK's sale of linerixibat global rights for up to $690 million [4][16] - Merck's termination of its collaboration with Hengrui for the global rights to HRS-1167, originally valued at €1.4 billion, reflects a trend of prioritizing high-potential projects [4][16] Major Events in the Global Biopharmaceutical Industry - Vertex's Povetacicept shows promising results in treating IgA nephropathy, with a 49.8% reduction in 24-hour urine protein creatinine compared to placebo [9] - GSK's licensing agreement with Alfasigma for linerixibat includes a $300 million upfront payment and potential milestone payments totaling up to $690 million [6][16] Important Clinical Developments - Vertex's Povetacicept demonstrates significant clinical efficacy in a Phase III trial, indicating a potential shift in treatment paradigms for IgA nephropathy [9] - New clinical data from various companies, such as Ultragenyx's Avalotcagene ontaparvovec, shows a 18% reduction in plasma ammonia levels in patients with ornithine transcarbamylase deficiency [10][12] Investment and Transaction Events - The report details multiple financing rounds, including over $100 million raised by Aikang Bio in Series A3 funding, and nearly $100 million raised by Yili Pharma [17][20] - The strategic collaboration between Huazhong Pharmaceutical and Roche aims to enhance the commercialization of T-DM1 in mainland China, leveraging both companies' strengths [26] Regulatory Dynamics - The report notes significant regulatory approvals in China, including the approval of innovative drugs for chronic kidney disease and vitiligo, indicating a supportive regulatory environment for new therapies [29][30] - The FDA has streamlined the development process for biosimilars, which may enhance the market entry of new products and improve patient access [34][35]

Macro and Strategy Research - The US non-farm employment data for February was significantly below market expectations, continuing the slowdown trend since the end of 2025. The labor participation rate has slightly decreased after adjustments, and while the unemployment rate has increased, it remains within a controllable range. Inflation data appears stable, aligning with market expectations, but core goods are outperforming core services, indicating tariff transmission effects in sectors like apparel [2][3] - In Europe, the reliance on oil imports is higher, making the situation more challenging, with markets pricing in a potential interest rate hike by the European Central Bank this year [3] Fixed Income Research - February CPI showed an increase in both year-on-year and month-on-month growth, driven by seasonal factors and rising international oil prices, which also impacted PPI. The core inflation is expected to seasonally decline in March, with input factors remaining significant [6] - The central bank net injected 500 billion yuan into the market, with funding prices slightly rising. The issuance of bonds in the primary market decreased, with a total of 63 bonds issued, amounting to 414.2 billion yuan [6][8] - The long-term interest rates are under pressure due to rising inflation expectations, particularly from the increase in international oil prices. The market is advised to cautiously observe inflation changes in the short term [7][8] Industry Research - Eli Lilly has invested $3 billion to enhance its supply chain in China, indicating strong interest in the Chinese pharmaceutical market [9] - Several pharmaceutical companies have been added to the Hong Kong Stock Connect list, reflecting growing investor interest [10] - The SW pharmaceutical sector index rose by 2.49% during the week, with all sub-sectors showing gains. The overall industry P/E ratio is 49.25 times, with a valuation premium of 245% compared to the CSI 300 [10] - The report maintains a "neutral" rating for the industry, with specific buy and hold recommendations for companies like Heng Rui Medicine and WuXi AppTec, while also highlighting the potential impact of rising raw material prices on pharmaceutical companies [11]

Group 1 - China Biologic Products (01177.HK) announced that its subsidiary, Chengda Tianqing, has completed the interim analysis of the Phase III clinical study for TQB3454, an IDH1 inhibitor for advanced cholangiocarcinoma with IDH1 mutations, achieving the predefined efficacy thresholds for progression-free survival (PFS) and overall survival (OS) [1] - The study, TQB3454-III-01, is a randomized, double-blind, placebo-controlled, multi-center Phase III trial aimed at evaluating the efficacy and safety of TQB3454 in patients with advanced cholangiocarcinoma who have failed previous treatments [1] - The independent data monitoring committee (IDMC) determined that TQB3454 significantly reduces the risk of disease progression or death compared to the control group, significantly extending both PFS and OS [1] Group 2 - Cholangiocarcinoma (BTC) accounts for approximately 3% of all digestive system tumors, with over 200,000 new cases globally in 2021, and its incidence is on the rise [2] - BTC primarily consists of adenocarcinoma, characterized by high malignancy and poor prognosis, with a five-year survival rate of less than 5% [2] - IDH1 inhibitors are crucial for the precision treatment of cholangiocarcinoma, and currently, there are no approved drugs targeting this pathway in China, indicating a significant unmet clinical need [2]